Kimberly-Clark/$KMB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Kimberly-Clark

With more than half of its sales from personal care and another third from consumer tissue products, Kimberly-Clark is a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, PullUps, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates in the professional segment, partnering with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.

Ticker

$KMB
Primary listing

Employees

38,000

Kimberly-Clark Metrics

BasicAdvanced
$42B
17.62
$7.26
0.33
$4.96
3.94%

What the Analysts think about Kimberly-Clark

Analyst ratings (Buy, Hold, Sell) for Kimberly-Clark stock.

Bulls say / Bears say

Kimberly-Clark’s organic sales grew 3.9% in the second quarter, marking its strongest volume growth in five years, as its value-to-premium pricing approach lifted volumes by 5% despite a tough consumer backdrop (Reuters).
The company beat Q2 earnings expectations, delivering adjusted EPS of $1.92 per share versus analysts’ $1.67 estimate, prompting a third raise to its 2025 profit outlook, now targeting low-to-mid single-digit EPS growth (Reuters).
In June, Kimberly-Clark reached a deal to sell a majority 51% stake in its international tissue business to Suzano for $3.4 billion, freeing up capital and allowing a greater focus on its higher-margin personal care lines (Reuters).
New U.S. trade tariffs are expected to cost Kimberly-Clark approximately $300 million in 2025, leading the company to lower its profit outlook to flat-to-positive adjusted EPS growth, down from its previous mid-to-high single-digit forecast (Reuters).
First-quarter revenues dropped 6% year-over-year to $4.84 billion, impacted by tariff costs, the exit from its private-label diaper segment, and softer demand across North America and international personal care markets (Reuters).
Despite stronger volumes, Kimberly-Clark’s Q2 GAAP net sales from continuing operations fell 1.6% to $4.16 billion, as sales of businesses and strategic pricing moves limited total sales growth (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Kimberly-Clark Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Kimberly-Clark Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KMB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Oct2
Kimberly-Clark
DividendPayment
$1.26Per share
FAQs